Vallon Pharmaceuticals, Inc. (VLON)
| Market Cap | 33.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.46M |
| Shares Out | 6.81M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,868 |
| Open | 5.37 |
| Previous Close | 5.38 |
| Day's Range | 4.84 - 5.44 |
| 52-Week Range | 3.61 - 10.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About VLON
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvan...
Financial Performance
Financial StatementsNews
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for...
- Patent bolsters intellectual property protection as Company's partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Ap...
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines ...
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning
Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tue...
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
- Pivotal data from lead program, ADAIR, expected in second half 2021
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developm...
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
- Accomplished executive leader with more than 30 years of experience in finance and operations
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developmen...
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are ...
Micro-cap drug developer Vallon Pharmaceuticals sets terms for $15 million IPO
Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.
Vallon Pharmaceuticals IPO Registration Document (S-1)
Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.